BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomized CORE II study. Gut. 2014;63:433-441. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 154] [Cited by in F6Publishing: 133] [Article Influence: 17.1] [Reference Citation Analysis]
Number Citing Articles
1 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
3 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br J Clin Pharmacol 2018;84:239-51. [PMID: 29057539 DOI: 10.1111/bcp.13456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
5 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
7 Taylor CT, Doherty G, Fallon PG, Cummins EP. Hypoxia-dependent regulation of inflammatory pathways in immune cells. J Clin Invest 2016;126:3716-24. [PMID: 27454299 DOI: 10.1172/JCI84433] [Cited by in Crossref: 75] [Cited by in F6Publishing: 50] [Article Influence: 12.5] [Reference Citation Analysis]
8 Abdalla MI, Herfarth H. Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother. 2016;17:1549-1559. [PMID: 27157244 DOI: 10.1080/14656566.2016.1183648] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
9 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
10 Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci 2015;60:3408-17. [PMID: 26386854 DOI: 10.1007/s10620-015-3868-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
11 Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96-107. [PMID: 25466162 DOI: 10.1590/1414-431x20143774] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
12 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
14 Taylor K, Gibson PR. Conventional Therapy of Ulcerative Colitis: Corticosteroids. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Cham: Springer International Publishing; 2017. pp. 399-412. [DOI: 10.1007/978-3-319-33703-6_39] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
15 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
16 Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015;148:740-750.e2. [PMID: 25644096 DOI: 10.1053/j.gastro.2015.01.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 9.1] [Reference Citation Analysis]
17 Grevenitis P, Thomas A, Lodhia N. Medical Therapy for Inflammatory Bowel Disease. Surgical Clinics of North America 2015;95:1159-82. [DOI: 10.1016/j.suc.2015.08.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
18 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther. 2015;42:957-967. [PMID: 26304292 DOI: 10.1111/apt.13375] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
20 Debotton N, Dahan A. Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms: POLYMERS AS PHARMACEUTICAL EXCIPIENTS. Med Res Rev 2017;37:52-97. [DOI: 10.1002/med.21403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
21 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
23 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Naganuma M, Aoyama N, Suzuki Y, Nishino H, Kobayashi K, Hirai F, Watanabe K, Hibi T. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. J Crohns Colitis 2016;10:828-36. [PMID: 26577683 DOI: 10.1093/ecco-jcc/jjv208] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
25 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Reference Citation Analysis]
26 Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019;8:212572. [PMID: 31065290 DOI: 10.7573/dic.212572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
27 Bezzio C, Fascì-Spurio F, Viganò C, Meucci G, Papi C, Saibeni S. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology. Expert Rev Gastroenterol Hepatol 2017;11:33-41. [PMID: 27805459 DOI: 10.1080/17474124.2017.1256200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol. 2014;20:3751-3761. [PMID: 24744571 DOI: 10.3748/wjg.v20.il14.3751] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
30 Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ 2018;21:869-77. [PMID: 29857775 DOI: 10.1080/13696998.2018.1484371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Vestergaard T, Jørgensen SMD, Christensen LA, Julsgaard M. Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX. Scandinavian Journal of Gastroenterology 2018;53:1459-62. [DOI: 10.1080/00365521.2018.1533583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
33 Hong SJ, Galati J, Katz S. Crohn's Disease of the Elderly. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.014] [Reference Citation Analysis]
34 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bernstein CN. Spicing up the Treatment of Mild to Moderate Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2015;13:1450-2. [DOI: 10.1016/j.cgh.2015.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
36 Narula N, Rubin DT, Sands BE. Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. Am J Gastroenterol Suppl 2016;3:38-44. [DOI: 10.1038/ajgsup.2016.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
37 Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103. [PMID: 24641622 DOI: 10.1111/apt.12712] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
38 Cross RK. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1689-701. [DOI: 10.1097/mib.0000000000001261] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
39 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
40 Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 2015;41:409-18. [PMID: 25588902 DOI: 10.1111/apt.13076] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
41 Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. In: Feagan BG, Kahrilas PJ, Jalan R, Mcdonald JWD, editors. Evidence-based Gastroenterology and Hepatology 4e. Chichester: John Wiley & Sons, Ltd; 2019. pp. 173-86. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Miehlke S, Acosta MB, Bouma G, Carpio D, Magro F, Moreels T, Probert C. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician: Optimising therapy with budesonide. Journal of Gastroenterology and Hepatology 2018;33:1574-81. [DOI: 10.1111/jgh.14151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
43 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Reference Citation Analysis]
44 Duijvestein M, Battat R, Vande Casteele N, D’haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastro 2018;16:129-46. [DOI: 10.1007/s11938-018-0175-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
45 Sipponen MH, Lange H, Ago M, Crestini C. Understanding Lignin Aggregation Processes. A Case Study: Budesonide Entrapment and Stimuli Controlled Release from Lignin Nanoparticles. ACS Sustain Chem Eng 2018;6:9342-51. [PMID: 30271691 DOI: 10.1021/acssuschemeng.8b01652] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 17.5] [Reference Citation Analysis]
46 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Naeem M, Oshi MA, Kim J, Lee J, Cao J, Nurhasni H, Im E, Jung Y, Yoo JW. pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions. Nanomedicine 2018;14:823-34. [PMID: 29353017 DOI: 10.1016/j.nano.2018.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
48 Ghattamaneni NKR, Panchal SK, Brown L. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease. Pharmacol Res 2018;132:99-107. [PMID: 29680446 DOI: 10.1016/j.phrs.2018.04.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
49 Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9:507-515. [PMID: 25870198 DOI: 10.1093/ecco-jcc/jjv059] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 10.1] [Reference Citation Analysis]
50 Yan X, Yang C, Yang M, Ma Y, Zhang Y, Zhang Y, Liu C, Xu Q, Tu K, Zhang M. All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis. J Nanobiotechnology 2022;20:99. [PMID: 35236359 DOI: 10.1186/s12951-022-01299-8] [Reference Citation Analysis]
51 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
52 Salleron J, Danese S, D'Agay L, Peyrin-Biroulet L. Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. J Crohns Colitis 2016;10:1096-102. [PMID: 26944416 DOI: 10.1093/ecco-jcc/jjw068] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
53 Ungaro RC, Brenner EJ, Agrawal M, Zhang X, Kappelman MD, Colombel JF; Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology 2021:S0016-5085(21)03490-9. [PMID: 34529987 DOI: 10.1053/j.gastro.2021.09.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zhou H, Qian H. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. Drug Des Devel Ther 2018;12:2601-9. [PMID: 30174414 DOI: 10.2147/DDDT.S170676] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.8] [Reference Citation Analysis]
56 Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol 2019;114:733-45. [DOI: 10.14309/ajg.0000000000000111] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
57 Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2015;21:2948-57. [DOI: 10.1097/mib.0000000000000631] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Van Assche G, Manguso F, Zibellini M, Cabriada Nuño JL, Goldis A, Tkachenko E, Varoli G, Kleczkowski D, Annese V, D'Heygere F, Balzano A; BETA study participating centers. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol 2015;110:708-15. [PMID: 25869389 DOI: 10.1038/ajg.2015.114] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
59 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149:110-118.e4. [PMID: 25836986 DOI: 10.1053/j.gastro.2015.03.045] [Cited by in Crossref: 490] [Cited by in F6Publishing: 421] [Article Influence: 70.0] [Reference Citation Analysis]
61 Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). United European Gastroenterol J 2020;8:1186-95. [PMID: 33028169 DOI: 10.1177/2050640620962632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis 2015;9:738-46. [PMID: 26094251 DOI: 10.1093/ecco-jcc/jjv101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
64 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 20.3] [Reference Citation Analysis]
66 Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018;35:1746-1762. [PMID: 30374806 DOI: 10.1007/s12325-018-0795-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
67 Bezzio C, Festa S, Zerboni G, Papi C, Manes G, Saibeni S. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:437-44. [DOI: 10.1080/14740338.2018.1442432] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:748-64. [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
69 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
70 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
71 Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 2014;15:1659-70. [DOI: 10.1517/14656566.2014.925445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
72 D'haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016;44:1018-29. [DOI: 10.1111/apt.13803] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
73 Triadafilopoulos G. Glucocorticoid therapy for gastrointestinal diseases. Expert Opinion on Drug Safety 2014;13:563-72. [DOI: 10.1517/14740338.2014.904852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
74 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
75 Zeng J, Lv L, Mei Z. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis: Budesonide foam for ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:558-66. [DOI: 10.1111/jgh.13604] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
76 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
77 Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. Int J Nanomedicine 2015;10:4565-80. [PMID: 26213469 DOI: 10.2147/IJN.S87816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
78 Dorreen A, Heisler C, Jones J. Treatment of Inflammatory Bowel Disease in the Older Patient. Inflammatory Bowel Diseases 2018;24:1155-66. [DOI: 10.1093/ibd/izy023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
79 Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. United European Gastroenterol J 2019;7:1164-70. [PMID: 31700629 DOI: 10.1177/2050640619864257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
80 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
81 Magro F, Estevinho MM. Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis. United European Gastroenterol J 2019;7:1153-5. [PMID: 31700627 DOI: 10.1177/2050640619878588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
83 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
84 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
85 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 13.9] [Reference Citation Analysis]
86 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
87 Gareb B, Dijkstra G, Kosterink JGW, Frijlink HW. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. Int J Pharm 2019;554:366-75. [PMID: 30414898 DOI: 10.1016/j.ijpharm.2018.11.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
88 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
89 Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation. World J Gastroenterol 2014; 20(14): 3751-3761 [PMID: 24744571 DOI: 10.3748/wjg.v20.i14.3751] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 94] [Article Influence: 12.6] [Reference Citation Analysis]
90 Danese S, Bonovas S, Peyrin-Biroulet L. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis 2017;11:767-8. [PMID: 28333203 DOI: 10.1093/ecco-jcc/jjx025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, Basit AW. Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev 2021;181:114076. [PMID: 34890739 DOI: 10.1016/j.addr.2021.114076] [Reference Citation Analysis]
92 Gareb B, Eissens AC, Kosterink JGW, Frijlink HW. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease. Eur J Pharm Biopharm 2016;103:32-42. [PMID: 27000751 DOI: 10.1016/j.ejpb.2016.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
93 Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
94 Danese S, Peyrin-biroulet L. Enriching the therapeutic armamentarium for IBD. Nat Rev Gastroenterol Hepatol 2014;11:84-6. [DOI: 10.1038/nrgastro.2013.246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
95 Gao C, Yu S, Zhang X, Dang Y, Han DD, Liu X, Han J, Hui M. Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis. Int J Nanomedicine 2021;16:1405-22. [PMID: 33658780 DOI: 10.2147/IJN.S291090] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Muthas D, Reznichenko A, Balendran CA, Böttcher G, Clausen IG, Kärrman Mårdh C, Ottosson T, Uddin M, MacDonald TT, Danese S, Berner Hansen M. Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications. Scand J Gastroenterol 2017;52:125-35. [PMID: 27610713 DOI: 10.1080/00365521.2016.1235224] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
97 Löwenberg M, D’Haens G. Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21. [PMID: 26031830 DOI: 10.1007/s11894-015-0444-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
98 Łodyga M, Eder P, Bartnik W, Gonciarz M, Kłopocka M, Linke K, Małecka-Panas E, Radwan P, Rydzewska G. New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol 2015;10:57-60. [PMID: 26557934 DOI: 10.5114/pg.2015.52702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082-1092. [PMID: 26381802 DOI: 10.1111/apt.13387] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
100 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75:879-886. [PMID: 25920500 DOI: 10.1007/s40265-015-0396-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
101 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
102 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
103 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 27.1] [Reference Citation Analysis]
104 Turanlı Y, Acartürk F. Preparation and characterization of colon-targeted pH/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur J Pharm Sci 2022;171:106122. [PMID: 35007712 DOI: 10.1016/j.ejps.2022.106122] [Reference Citation Analysis]
105 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
106 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
107 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Kamboj AK, Cotter TG, Hicks SB, Tremaine WJ, Loftus EV Jr, Pardi DS. Extended-release Multimatrix Budesonide for Microscopic Colitis. Inflamm Bowel Dis 2017;23:E21-2. [PMID: 28328627 DOI: 10.1097/MIB.0000000000001090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
109 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
111 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
112 Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014;8:927-35. [DOI: 10.1016/j.crohns.2014.02.021] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis]
113 Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J 2019;7:1171-82. [PMID: 31700630 DOI: 10.1177/2050640619864848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
114 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
115 Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
116 Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci 2016;61:358-70. [PMID: 26541989 DOI: 10.1007/s10620-015-3897-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
117 Crouwel F, Buiter HJC, de Boer NK. Gut microbiota-driven drug metabolism in inflammatory bowel disease. J Crohns Colitis 2020:jjaa143. [PMID: 32652007 DOI: 10.1093/ecco-jcc/jjaa143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
118 Saibeni S, Meucci G, Papi C, Manes G, Fascì-Spurio F. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol 2014;8:949-62. [PMID: 24882015 DOI: 10.1586/17474124.2014.924396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
119 Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B. Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis. Gut 2015;64:901-10. [PMID: 25053717 DOI: 10.1136/gutjnl-2014-307618] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
120 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
121 Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11:785-791. [PMID: 28333362 DOI: 10.1093/ecco-jcc/jjx032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
122 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
123 Novaković A. Modern therapy for inflammatory bowel disease. Arhiv za farmaciju 2017;67:112-23. [DOI: 10.5937/arhfarm1702112n] [Reference Citation Analysis]
124 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
125 Naeem M, Bae J, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, Yoo JW. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. Int J Nanomedicine 2018;13:1225-40. [PMID: 29535519 DOI: 10.2147/IJN.S157566] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
126 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
127 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
128 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
129 Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterol 2016;3:e000092. [PMID: 27239329 DOI: 10.1136/bmjgast-2016-000092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
131 Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742-53. [PMID: 30122356 DOI: 10.1016/S2468-1253(18)30231-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
132 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
133 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
134 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
135 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
136 Naeem M, Yoo J. Withdrawn: Budesonide-loaded enzyme- and pH-sensitive polymeric nanoparticles for the treatment of colitis. Asian Journal of Pharmaceutical Sciences 2015. [DOI: 10.1016/j.ajps.2015.11.089] [Reference Citation Analysis]
137 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
138 James SL, van Langenberg DR, Taylor KM, Gibson PR. Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). JGH Open 2018;2:217-22. [PMID: 30483593 DOI: 10.1002/jgh3.12076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Fujiya M, Ueno N, Kashima S, Tanaka K, Sakatani A, Ando K, Moriichi K, Konishi H, Kamiyama N, Tasaki Y, Omura T, Matsubara K, Taruishi M, Okumura T. Long-Chain Polyphosphate Is a Potential Agent for Inducing Mucosal Healing of the Colon in Ulcerative Colitis. Clin Pharmacol Ther 2020;107:452-61. [PMID: 31513280 DOI: 10.1002/cpt.1628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
140 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
141 Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S, Lee J, Moon HR, Kim MS, Jung Y, Yoo JW. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther 2015;9:3789-99. [PMID: 26229440 DOI: 10.2147/DDDT.S88672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
142 Salice M, Rizzello F, Calabrese C, Privitera Hrustemovic H, Gionchetti P. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2019;13:607-13. [DOI: 10.1080/17474124.2019.1621745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]